Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of cenegermin versus vehicle for persistent corneal epithelial defect
2025-523443-35-00Phase 3Authorised
- Sponsor
- Dompé
- Start
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in corneal persistent epithelial defect (PED) comparing Cenegermin with Vehicle control (2 arms). Primary endpoint: Complete epithelial healing at week 4 maintained at week 8. Planned start Jun 2026; status: authorised.
02
Drugs
cenegermin
03
Conditions
corneal persistent epithelial defect (PED)
Beyond the preview
Go deeper on 2025-523443-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523443-35-00.